Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE plus camrelizumab with or without apatinib for unresectable hepatocellular carcinoma
ChiCTR2100051197Phase 2Recruiting
- Sponsor
- Xi'an International Medical Center Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Xi'an International Medical Center Hospital. Primary endpoint: Progression-free survival by RECIST 1.1. Started Sep 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100051197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051197.